

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of treating ~~or preventing~~ a pathological condition of the uterus in a female individual, the method comprising:  
 administering to ~~the a female individual, having a pathological condition of the uterus associated with abnormal growth of cells of the myometrium or endometrium, an at least one agent that prevents~~ PGF<sub>2α</sub> having its effect on the FP F prostanoid (FP) receptor antagonist under conditions effective to treat the pathological condition of the uterus.

2. (Cancelled)

3. (Previously Presented) A method according to Claim 1 wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.

4. (Original) A method according to Claim 3 wherein the endometrial pathological condition is endometriosis.

5. (Original) A method according to Claim 3 wherein the myometrial pathological condition is fibroids.

6-8. (Cancelled)

9. (Currently Amended) A method according to ~~Claim 8~~ Claim 1 wherein the FP receptor antagonist is any one or more of PGF<sub>2α</sub> dimethyl amide; PGF<sub>2α</sub>, dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2α</sub>); phloretin; glibenclamide; ridogrel; PHG113, PCP-1 (rvkfsqqhrqgrshhlem); PCP-2 (rkavlknllyklasqccgvhvislhiwelssiknslkvaaaisespvaeksast); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH<sub>2</sub>); PCP-4 (kdtlqlnlkeynlv-NH<sub>2</sub>); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCISIF).

10-11. (Cancelled)

12. (Currently Amended) A method according to Claim 1 further comprising administering to the individual an inhibitor of PGES and/or an antagonist of the E prostanoid receptor 2 (EP2 receptor) or E prostanoid receptor 4 (EP4 receptor) EP2 or EP4.

13. (Currently Amended) A method according to Claim 12 wherein the antagonist of the EP2 or EP4 receptor is one or more of AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, a peptide selected from the group consisting of those having the amino acid sequence IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, ILASYECL, IFTSTDCL, XTSYEAL (where X is 4-biphenylalanine), and XTSYEAL (where X is homophenylalanine), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one.

14-31. (Cancelled)